Asia FX muted, dollar nurses losses as Trump tariffs take effect
BOSTON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) announced Tuesday that Raju Kucherlapati has stepped down from his position as Chair and member of the Board of Directors after nearly two decades with the company.
Sharon Barber-Lui, the company’s Audit Committee Chair, has been appointed as Interim Chair of the Board. She will lead the process to identify a permanent replacement and engage with shareholders to gather input on board evolution criteria.
"Raju has been an integral part of PureTech’s journey for almost two decades, and we are deeply grateful for his dedication and leadership," said Bharatt Chowrira, PureTech’s Chief Executive Officer, in a press release statement.
Robert Langer, PureTech’s Co-founder and board member, acknowledged Kucherlapati’s contributions, stating, "Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry."
During his tenure, Dr. Kucherlapati helped guide PureTech from its startup phase to an established biotherapeutics company. The clinical-stage firm focuses on developing therapeutics for patients with serious diseases and has developed 29 therapeutic candidates, including three that have received FDA approval.
PureTech’s most recent achievements include the FDA approval of Cobenfy and the launch of Seaport Therapeutics, one of its Founded Entities.
The company did not provide specific reasons for Dr. Kucherlapati’s departure in its announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.